Eczema as a Barrier and Immune Condition, Why Skin Integrity Matters

Eczema is often described as an allergic skin condition, but for many people, this explanation falls short. Chronic flares, worsening dryness, persistent itch, and cycles of improvement followed by relapse suggest that eczema is not driven by allergy alone.

For many individuals, the missing piece is not identifying a single trigger, but understanding how skin barrier damage and immune imbalance reinforce one another and keep inflammation active.

The Skin Barrier, Where Eczema Begins

Eczema starts with a weakened skin barrier. The outermost layer of the skin, called the stratum corneum, is designed to keep moisture in and irritants, microbes, and allergens out. In eczema, this barrier does not function properly.

Structural changes in the skin, including reduced filaggrin protein and altered lipid composition, increase water loss and allow external substances to penetrate more easily¹. This makes the skin more reactive and vulnerable, even in the absence of obvious allergens.

This helps explain why many people continue to flare despite strict avoidance diets or negative allergy testing. The skin is responding to constant exposure through a compromised barrier, not a single identifiable trigger.

Immune Imbalance and Ongoing Inflammation

Once the skin barrier is impaired, immune activation follows. Eczema is associated with immune signaling patterns that favor inflammation, particularly pathways involving Th2 immune responses, with additional contributions from Th17 and Th22 signaling depending on age, genetics, and disease duration².

Key inflammatory messengers, including IL-4 and IL-13, further suppress filaggrin production and lipid synthesis in the skin. This prevents proper barrier repair and locks the skin into a cycle of inflammation and fragility.

In this way, barrier damage drives immune activation, and immune activation prevents the barrier from healing.

Itch, More Than a Symptom

Itch is not just an uncomfortable side effect of eczema, it is a central driver of disease severity. Immune signaling molecules such as IL-31 directly stimulate itch pathways, leading to scratching behavior that mechanically damages the skin.

Scratching worsens barrier disruption, increases microbial colonization, and intensifies immune activation. In many cases, itch severity correlates more strongly with disease burden than visible redness or rash.

Breaking the itch–scratch cycle is critical for long-term improvement.

The Role of Skin Microbes

Healthy skin supports a diverse microbial ecosystem. In eczema, this diversity is often reduced, with increased colonization by Staphylococcus aureus. This bacterium produces toxins that activate the immune system broadly, increasing cytokine release and worsening inflammation³.

Rather than being a simple infection, this microbial shift reflects an ecosystem imbalance driven by barrier failure and immune dysregulation.

Shifting the Focus, From Suppression to Repair

A barrier-centered understanding of eczema shifts the goal away from short-term suppression and toward long-term repair. Supporting eczema-prone skin involves:

• Rebuilding lipid structure and moisture retention
• Reducing immune hyperreactivity
• Supporting microbial balance on the skin
• Minimizing repeated barrier disruption

When the skin barrier becomes more resilient, immune signaling often quiets naturally.

Understanding the Bigger Picture

Eczema is best understood as a barrier and immune condition. When symptoms persist despite treatment, ongoing barrier dysfunction is often the missing variable.

Restoring skin integrity is not just supportive care, it is central to calming inflammation and reducing flare frequency over time.

References

1. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446.
2. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11.
3. Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in atopic dermatitis. Genome Res. 2012;22(5):850–859.